Teriflunomide: A Once-Daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
September 2015
in “
Clinical Therapeutics
”
Studysummary This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea. Our plain-language summary of this paper — not a Tressless recommendation.
Teriflunomide was an FDA-approved oral medication for relapsing multiple sclerosis, demonstrating significant efficacy in reducing relapse rates and disease progression in clinical trials. The 14-mg dose notably reduced the annualized relapse rate by up to 36% and decreased disability progression risk, while the 7-mg dose was less effective in preventing disability progression. MRI results supported its efficacy by showing reduced lesion volume. Common adverse events included headache, increased liver enzymes, diarrhea, and alopecia. Due to potential teratogenic effects, it was contraindicated in pregnancy, and routine monitoring was recommended. Overall, teriflunomide was considered an effective treatment option with a favorable benefit-risk profile.
